liraglutide

Known as: N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide, Liraglutide [Chemical/Ingredient], N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide 
A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2017
010020030019882017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients… (More)
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Agonists of the glucagon-like peptide-1 (GLP-1) receptor provide pharmacological levels of GLP-1 activity, whereas… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
AIM To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently… (More)
Is this relevant?